HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PHG
Koninklijke Philips N.V.
PHG's fundamentals are strong: its operating margin rose 4 points to 9.7% and earnings per share more than tripled. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PHG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Healthy |
PHG's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PHG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7x | $9.06 | -70% |
| Current | 23x | $30.05 | — |
| Fair | 29x | $37.91 | +26% |
| Expensive | 40x | $51.41 | +71% |
Historical ranges are pointers, not guarantees.
PHG's PE is 23x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PHG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
PHG has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
PHG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $1.29 | +579% |
| Q1 2026 | $1.12 | +155% |
| Q4 2025 | $1.03 | +$1.90 |
| Q3 2025 | $0.18 | +$0.61 |
| Q2 2025 | $0.19 | +$0.73 |
| Q1 2025 | $0.44 | +$1.43 |
| Q1 2024 | -$0.99 | +$1.60 |
| Q1 2023 | -$2.59 | -171% |
PHG has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over PHG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PHG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.8B | +0.5% |
| Q1 2026 | $4.3B | -4.7% |
| Q4 2025 | $5.7B | +1.1% |
| Q3 2025 | $4.8B | -1.7% |
| Q2 2025 | $4.8B | -2.8% |
| Q1 2025 | $4.6B | -1% |
| Q4 2024 | $5.6B | -0.4% |
| Q3 2024 | $4.9B | -2.1% |
PHG's revenue fell from its 2020 peak and has held roughly level since: $4.8B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 14% | +4.8 points |
| Q1 2026 | 6.2% | +2.4 points |
| Q4 2025 | 11% | +6.6 points |
| Q3 2025 | 7.7% | 0 points |
| Q2 2025 | 9.2% | -9.1 points |
| Q1 2025 | 3.8% | +24 points |
| Q4 2024 | 4% | +3.5 points |
| Q3 2024 | 7.7% | +2.7 points |
PHG has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over PHG on cash flow, with more consistent year-over-year improvement.
PHG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $243.3M | -3.9% |
| Q1 2026 | $129.9M | +$1.3B |
| Q4 2025 | $1.5B | +$1.5B |
| Q3 2025 | $287.7M | +$287.7M |
| Q2 2025 | $253.3M | +$331M |
| Q1 2025 | -$1.2B | -$776.3M |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
PHG's free cash flow is usually positive and has bounced back after one negative quarter: $2.1B over the past year, against −$902M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PHG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PHG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +44K shares |
| 1 year | +1.2% | +11.9M shares |
| 3 years | +2.3% | +22M shares |
| 5 years | +1.3% | +12.3M shares |
| Available history | +0.6% | +6.2M shares |
PHG has 969M diluted shares, up 1.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $75.5M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
PHG spent $76M buying back its own shares over the past year, after none the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over PHG on leverage, with a lower net debt burden relative to earnings.
PHG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.9x | Healthy |
| Q1 2026 | 2.0x | Moderate |
| Q4 2025 | 2.0x | Moderate |
| Q3 2025 | 3.0x | Moderate |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 3.5x | Elevated |
| Q4 2024 | 6.2x | High |
| Q3 2024 | -1.5x | Net Cash |
PHG's net debt is about 1.9 years of its operating earnings (EBITDA), down from 3.5 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PHG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.3 | Neutral |
| Stochastic | 84.8 | Overbought |
PHG's weekly RSI is 64 (neutral) and its Stochastic is 85 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PHG PE vs Healthcare Sector
| Metric | PHG | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 9.8% below |
| PE % | 29 | 29 | Same percentile |
PHG is trading at 23x earnings, in line with the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PHG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.6 | 13% above |
| 20 week MA | $26.6 | 13% above |
| 50 week MA | $27.4 | 9.9% above |
| 100 week MA | $26.7 | 13% above |
| 200 week MA | $24.5 | 23% above |
PHG has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PHG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.5 | $49.8 | +12% |
| 2021 | $49.8 | $33.6 | -33% |
| 2022 | $33.6 | $14.9 | -56% |
| 2023 | $14.9 | $22.6 | +51% |
| 2024 | $22.6 | $25.6 | +13% |
| 2025 | $25.6 | $27.1 | +6% |
| 2026 YTD | $27.1 | $30.1 | +11% |
PHG has the edge over HIMS on returns for 2026, with the stronger performance.